Navigation Links
PharmAthene Reports First Quarter 2012 Financial Results
Date:5/8/2012

ANNAPOLIS, Md., May 8, 2012 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported its financial results for the first quarter ended March 31, 2012.

Eric I. Richman, President and Chief Executive Officer, commented, "We are off to a great start in 2012 in regards to accomplishing our strategic objectives and meeting our financial goals. We are excited to continue our clinical evaluation of SparVax™ and are moving forward with plans to begin a Phase II clinical trial of SparVax™ later this year.  And, while we achieved positive cash flow from operations for the quarter, we also bolstered our financial position by securing a $7.5 million financing from GE Capital, Healthcare Financial Services, which further enhances our balance sheet and extends our cash runway into 2013, when we anticipate achieving final resolution of the litigation with SIGA Technologies."

"With respect to the SIGA litigation, we are currently awaiting final judgment from the Delaware Court of Chancery regarding its September 2011 decision to award PharmAthene a significant stake in SIGA's smallpox antiviral, ST-246," Mr. Richman continued.  "SIGA has said it expects to begin delivery of ST-246 under its $433 million contract with the U.S. Government in the first quarter of 2013."

First Quarter 2012 Financial ResultsRevenueFor the first quarter ended March 31, 2012, PharmAthene recognized revenue of $6.1 million, compared to $6.3 million for the same period in 2011.  Revenue in the first quarter of 2012 was primarily from development contracts with the U.S. government for the Company's SparVax™ and rBChE bioscavenger programs. 

Operating ExpensesResearch and development expenses for the three months ended March 31, 2012
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
2. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
3. PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
4. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
5. PharmAthene Reports Third Quarter 2011 Financial and Operating Results
6. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
7. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
8. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
9. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
10. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
11. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 6, 2015  Approximately 1% of the population inherits ... chromosomes. These individuals are three times more likely to ... one of the nation,s leading medical journals by researchers ... Photo - http://photos.prnewswire.com/prnh/20150706/230685 ... causes roseola (also known as "sixth disease") and occasional ...
(Date:7/6/2015)... ... 06, 2015 , ... Discovery of new biomarkers for patient ... of the global molecular diagnostics market. BCC Research reveals in its new report ... diagnostic tests will increase demand for inexpensive and accurate tests for genetic compatibility ...
(Date:7/6/2015)... July 6, 2015  Viveve Medical, Inc. ("Viveve") (OTCQB: VIVMF), a ... Scheller , Viveve,s Chief Executive Officer, and Scott Durbin ... on July 9, 2015. , , , DATE:    ... , , , TIME:     , , , 12:15 ... , , http://tinyurl.com/viveve   , ...
(Date:7/6/2015)... , July 6, 2015 ImmunoCellular Therapeutics, ... of an agreement with Novella Clinical (Novella), ... in patients with newly diagnosed glioblastoma. Novella is a ... services to small to mid-sized oncology companies. The ICT-107 ... in the US, Europe and ...
Breaking Biology Technology:Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 2Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 3Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 2Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 3Viveve to Webcast Live at VirtualInvestorConferences.com 2Viveve to Webcast Live at VirtualInvestorConferences.com 3ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2
... Netsmart, the leading provider of clinical solutions for ... Netsmart clients have so far received or are on ... funds for the Meaningful Use of an Electronic Health ... Use funding commitments announced to date for behavioral health ...
... 2011  Brinson Patrick Securities Corporation, a boutique investment bank specializing ... in the U.S. raised $25 million through activity of nine ... this year. While the data represent a ... life sciences sector compared to the second quarter of 2011, ...
... , Dr. Vivek Desai, MD, Hosmac India Pvt. Ltd. ... Clear winner under Healthcare & Biotech Category ... his hat of success at the felicitation ceremony of ,ET ... Managing Director, Hosmac India Pvt. Ltd. is now doubly charged ...
Cached Biology Technology:Netsmart Clients to Receive Nearly $2 Million in Meaningful Use EHR Incentive Payments 2Netsmart Clients to Receive Nearly $2 Million in Meaningful Use EHR Incentive Payments 3Netsmart Clients to Receive Nearly $2 Million in Meaningful Use EHR Incentive Payments 4Netsmart Clients to Receive Nearly $2 Million in Meaningful Use EHR Incentive Payments 5At-the-Market Offerings (ATM) of Life Sciences Companies Perform Well in Weak Follow-on Financing Environment of Third Quarter 2At-the-Market Offerings (ATM) of Life Sciences Companies Perform Well in Weak Follow-on Financing Environment of Third Quarter 3Sweet Success for Hosmac India Pvt. Ltd. at ET NOW-IndiaMART Leaders of Tomorrow Awards 2011 2Sweet Success for Hosmac India Pvt. Ltd. at ET NOW-IndiaMART Leaders of Tomorrow Awards 2011 3
(Date:6/17/2015)... Germany , June 17, 2015 ... Standard: QIA) today launched new Investigator ® STR assay ... the United States . The new genetic ... key genomic markers (short tandem repeats or STRs) for DNA ... evaluate the quality of DNA in each sample, a novel ...
(Date:6/16/2015)... Sweden , June 16, 2015 ... all touch fingerprint sensors in the company,s portfolio from one ... Deliveries are planned to mainly take place during the third ... in Asia . Jörgen Lantto, ... evidence of    the   growing interest from smartphone OEMs ...
(Date:6/12/2015)... , June 12, 2015  Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... its patent to electronically capture, analyze and identify ... facial recognition methods. This system can: ... by an enrollment and subsequent sign-on process is ...
Breaking Biology News(10 mins):QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2
... While some published research has hinted at the connection ... among young, athletic African-American males, which was initially observed ... study with the first sizeable patient series definitively confirms ... The sickle cell trait, for which all U.S. African ...
... time, scientists have identified tropical and subtropical species of ... traveled thousands of miles on Atlantic currents and ended ... warm water, not as a direct result of overall ... arctic waters are warming rapidly, and such pulses are ...
... Gould once asked: If we rerun the tape of life, ... scientists have questioned whether evolution is predictable, or whether chance ... July 23 in the Proceedings of the National Academy ... that developed resistance to a powerful plant toxin, the same ...
Cached Biology News:Sickle cell trait can cause sudden cardiac death in black athletes: Why is this controversial? 2Sickle cell trait can cause sudden cardiac death in black athletes: Why is this controversial? 3Tropical plankton invade Arctic waters 2Tropical plankton invade Arctic waters 3Tropical plankton invade Arctic waters 4Tropical plankton invade Arctic waters 5Same adaptations evolve across different insects 2
... ester can be used to ... The covalently bound acridinium NHS ... the presence of hydrogen peroxide. ... be used as a detection ...
... up to 6 strain chambers with precise uniaxial ... design ensures that cells grow over long periods ... This unit allows you to control the frequency ... unique strain settings. The instrument fits in a ...
... a novel procedure for the uniform amplification ... genome DNA from small samples. This method ... and highly reproducible amplification and labeling procedure ... REPLI-g Mini Kit module (QIAGEN) and a ...
... using PULSin may be superior to transfection ... traditional transfection, with PULSin you can study ... time course of proteins in cells. Likewise, ... information than traditional RNA interference experiments. ...
Biology Products: